Volume 23, No 8, Aug 2013

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 23 Issue 8, August 2013: 975-977

RESEARCH HIGHLIGHTS

Differentiation therapy for IDH1/2 mutant malignancies

Francine E Garrett-Bakelman¹ and Ari M Melnick^1,2

¹Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, 1300 York Ave., New York, NY 10065, USA
²Department of Pharmacology, Weill Cornell Medical College, 1300 York Ave., New York, NY 10065, USA Correspondence: (amm2014@med.cornell.edu)

Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietic and glial cells. Two recent reports in Science describe the first IDH1 and IDH2 mutant-specific small-molecule inhibitors, which induce cell differentiation of myeloid leukemias and malignant gliomas.

10.1038/cr.2013.73

FULL TEXT | PDF

Browse 2204